{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 56,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/15",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.43,
        "y": 0.65
      },
      "kind": "callout",
      "text": "Improvement in ORR and DCR of binimetinib vs. dacarbazine translated to improvement in PFS",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da35334c-a0f1-48ff-b5b7-6bc54ca04727",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "NEMO trial (Lancet Oncol (2017) 18: 435-445) benchmarks are most relevant for SC-2 although study was conducted in a 1/2L setting; IO = immuno-oncology. Limited difference in OS between dacarbazine and binimetinib potentially impacted by 46% of binimetinib and 44% of dacarbazine patients receiving subsequent IO after coming off the trial;",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bed1acf-3ced-44cf-859e-fe4fd481f77d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.09,
        "y": 0.25
      },
      "kind": "list",
      "text": "Front line: IO mono or combo (nivolumab, pembrolizumab, nivolumab + ipilimumab)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4653cbdb-3459-4f92-8ac6-76e758dc2eaa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.48,
        "x": 0.43,
        "y": 0.25
      },
      "kind": "list",
      "text": "Second line plus: Chemo is currently the approved post-IO therapy; Binimetinib (MEKi) is not approved but is available in the US via a compendial listing and off label use",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d85f1c0-0ee6-4469-b496-e006956481c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.45,
        "x": 0.45,
        "y": 0.45
      },
      "kind": "table",
      "text": "SOC: Dacarbazine (7% ORR, 24% DCR, 1.5m PFS, 10.1m OS); Binimetinib (15% ORR, 56% DCR, 2.8m PFS, 11.0m OS)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f3db91e-f03b-482f-ac27-15bbef675980",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Current approved standard of care post-IO for NRASm metastatic melanoma is chemotherapy (with 7% ORR and 1.5m PFS in 1/2L setting)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27e8e4a7-e46f-4630-b40f-d10d45cdcd20",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "c48fd404-edfd-4163-921c-1a2fb5df192a",
      "evidence": "Current approved standard of care post-IO for NRASm metastatic melanoma is chemotherapy",
      "confidence": 0.7
    },
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "43f09b7c-3c8d-482a-967c-a0c994cdd3a1",
      "evidence": "table/data: SOC: Dacarbazine (7% ORR, 24% DCR, 1.5m PFS, 10.1m OS); Binimetinib (15% ORR, 56% DCR, 2.8m PFS, 11.0m OS)",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 15,
      "beatId": "083e76e7-2308-4452-b206-48463d7bb6e5",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document identifies the current standard of care for NRASm metastatic melanoma and its limitations.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 20,
      "from": 15,
      "beatId": "0ba8dc28-f394-4539-9ceb-99555f1271c2",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document highlights the unmet needs and limitations of current treatments for NRASm metastatic melanoma.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    },
    {
      "to": 20,
      "from": 13,
      "beatId": "f286216e-8f02-4c67-ba26-139ada264780",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document provides evidence and proof of Erasca's pipeline and its potential effectiveness.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1dd29138-5e83-440f-a4ea-0cd29a31a0c3",
      "evidence": "The document highlights the limitations of current treatments and the potential benefits of Erasca's pipeline.",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet needs in cancer treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}